Purple Biotech Ltd (TLV: PPBT)

Market Cap	32.54M
Revenue (ttm)	n/a
Net Income (ttm)	-43.34M
Shares Out	516.55M
EPS (ttm)	-0.20
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,189,714
Open	7.20
Previous Close	7.20
Day's Range	6.60 - 7.20
52-Week Range	4.30 - 36.80
Beta	0.29
Analysts	n/a
Price Target	n/a
Earnings Date	Feb 6, 2025

About Purple Biotech

Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin recept...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1968
• Employees: 20
• Stock Exchange: Tel Aviv Stock Exchange
• Ticker Symbol: PPBT

Financial Performance

Financial numbers in USD